2型糖尿病对非酒精性脂肪性肝病的影响

2型糖尿病与非酒精性脂肪性肝病关系密切,其对非酒精性脂肪性肝病流行病学与抗糖尿病治疗对非酒精性脂肪性肝病病情转归均有影响。此文就2型糖尿病对NAFLD发病、进展及抗糖尿病治疗中生活方式干预和胰岛素增敏剂应用对NAFLD的影响作一综述,旨在为临床决策提供参考。     

Nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus and its association with cardiovascular disease

Introduction

Non-alcoholic fatty liver disease (NAFLD) encompasses a wide spectrum of liver disease that ranges from hepatic steatosis to non-alcoholic steatohepatitis. Obesity and diabetes mellitus are the prime risk factors for NAFLD. The aim of this study was to find out the prevalence of NAFLD among patients with type 2 diabetes mellitus and to detect the association of NAFLD with cardiovascular disease in them.

非酒精性脂肪肝和2型糖尿病与颈动脉病变的关系

目的探讨非酒精性脂肪肝(NAFLD)和2型糖尿病(T2DM)与颈动脉病变的关系。方法按是否有T2DM和NAFLD分为4组:对照组、NAFLD组、T2DM组、T2DM合并NAFLD组,观察各组临床及生化特征、颈动脉内-中膜厚度(IMT)以及超声分型,并对出现的颈动脉斑块形态、特点和颈动脉斑块积分进行分析。结果 T2DM合并NAFLD组的HOMA胰岛素抵抗指数高于其他三组;单纯T2DM组和NAFLD组HOMA-IR、TC、TG、LDL-C和BMI高于对照组,HDL-C低于对照组。T2DM合并NAFLD组IMT与其他三组比较,差异显著(P<0.05);T2DM组、NAFLD组IMT也大于对照组(P<0.05)。颈动脉硬化超声分型各组之间构成比的比较有差异。T2DM合并NAFLD组不稳定斑块形成高于T2DM组、NAFLD组,颈动脉斑块积分也较T2DM组、NAFLD组增多。结论NAFLD、T2DM与胰岛素抵抗、血脂异常、肥胖密切相关,易引起动脉粥样硬化,T2DM合并NAFLD与动脉粥样硬化斑块不稳定性和斑块发生程度之间有一定关联。     

非酒精性脂肪性肝病合并T2DM患者肠道菌群结构变化研究*

目的 探讨非酒精性脂肪性肝病(NAFLD)合并2型糖尿病(T2DM)患者肠道菌群结构的变化。方法 2018年6月～2020年7月我院诊治的NAFLD合并T2DM患者58例、NAFLD患者66例和健康人60例,采用二代基因测序技术,针对16 srRNA基因V3～V4高变序列进行扩增测序,通过与肠道菌群GENBA-NK数据库进行序列比对,分析肠道菌群的种类和结构。采用化学发光法测定血清空腹胰岛素(FINS),并计算稳态模型胰岛素抵抗(HOMA-IR)指数;采用ELISA法测定血清肿瘤坏死因子-α(TNF-α),采用免疫层析法测定血清超敏C反应蛋白(hs-CRP)。结果 NAFLD合并T2DM组粪拟杆菌门显著高于NAFLD组或健康人(P＜0.05),NAFLD组粪拟杆菌门又显著高于健康人(P＜0.05);NAFLD合并T2DM组粪厚壁菌门、柔嫩梭菌属、厌氧棍状菌属和布劳特菌属丰度均显著低于NAFLD组或健康人(P＜0.05),NAFLD组厚壁菌门、柔嫩梭菌属、厌氧棍状菌属和布劳特菌属丰度又均显著低于健康人(P＜0.05);NAFLD合并T2DM组HOMA-IR指数、血清TNF-α和hs-CRP水平分别为(2.8±1.3)、(52.3±11.7)ng/mL和(2.3±1.1)mg/L,显著高于NAFLD组【分别为(1.6±0.7)、(48.7±10.2)ng/mL和(1.6±0.9)mg/L,P<0.05】或健康人【分别为(1.3±0.3)、(33.2±8.4)ng/mL和(1.2±0.4)mg/L,P<0.05】。结论 NAFLD合并T2DM患者存在胰岛素抵抗和血清炎性因子水平的变化,而且肠道菌群结构也发生了显著的改变,需进一步研究其临床意义。     

Comparison of effects of obesity and non-alcoholic fatty liver disease on incidence of type 2 diabetes mellitus

AIM: To compare and analyze the effects of obesity and non-alcoholic fatty liver disease (NAFLD) on the incidence of type 2 diabetes mellitus (T2DM) in Chinese subjects.METHODS: In 2008, a population of 4847 subjects was randomly sampled from 17 medical units for enrollment in this cohort study. Baseline information was obtained via a questionnaire on general information, physical examination (height, weight, and blood pressure), laboratory tests (triglycerides, total cholesterol, fasting blood glucose, alanine aminotransferase (ALT), uric acid, and creatinine), B-mode ultrasound, and ECG screening. The incidence of T2DM after four years of follow-up was calculated. Numeric variable data was tested for normality, with the data expressed as mean ± SD. Kaplan-Meier analysis was performed to calculate the cumulative incidence. The Cox proportional hazards model was used to analyze the relative risk (RR) of different body mass index (BMI) levels and NAFLD on T2DM, as well as analyzing the RR adjusted for age, sex, blood pressure, lipids, transaminases, uric acid, and creatinine.RESULTS: A total of 4736 (97.71%) subjects completed 4-year follow-up, with a median follow-up time of 3.85 years, totaling 17223 person-years. 380 subjects were diagnosed with T2DM, with a cumulative incidence of 8.0%. The cumulative incidence of T2DM in the NAFLD and control groups was 17.4% vs 4.1% (P < 0.001), respectively, while the incidence in overweight and obese subjects was 11.0% vs 15.8% (P < 0.001), respectively. The incidence of T2DM increased with an increase in baseline BMI. Cox regression analysis showed that the risk of T2DM in the NAFLD group (RR = 4.492, 95%CI: 3.640-5.542) after adjustment for age, sex, blood pressure, lipids, ALT, uric acid, and creatinine was 3.367 (2.367-4.266), while the value (RR, 95%CI) in overweight and obese subjects after adjustment for age, sex, BMI, blood pressure, lipids and other factors was 1.274 (0.997-1.629) and 1.554 (1.140-2.091), respectively. Stratification of three BMI levels (BMI < 24 kg/m², 24 kg/m² ≤ BMI < 28 kg/m², BMI ≥ 28 kg/m²) showed that the risk of T2DM in the NAFLD group was significantly higher than that in the control group (RR = 3.860, 4.049 and 3.823, respectively).CONCLUSION: Compared with BMI, NAFLD could be better at forecasting the risk of T2DM in Chinese subjects, and may be a high risk factor for T2DM, independent of overweight/obesity.     

Prevalence of coeliac disease in patients with non-alcoholic fatty liver disease

Background and study aimsCoeliac disease (CD) may be associated with several liver disorders including primary biliary cirrhosis, primary sclerosing cholangitis and autoimmune hepatitis. Furthermore preliminary data suggest a causative role of CD in steatosis and steatohepatitis. The aim of present study was to determine the prevalence of CD in a series of patients with non-alcoholic fatty liver disease (NAFLD).Patients and methodsIn a cross sectional study (2008–2010), 403 consecutive NAFLD patients (127 female and 276 male) referred to GI clinics of the Zahedan University of Medical Sciences were included. IgA anti-tissue transglutaminase (Anti-tTG) was used for screening of coeliac disease. In the patients with a positive serologic test, duodenal biopsies were taken to confirm the diagnosis.ResultsThe mean ± SD of the age and BMI of patients were 37.4 ± 12.4 years and 28.3 ± 4.15 kg/m² respectively. BMIs lower than 25 kg/m² were found in 58 subjects (14.5%). Furthermore diabetes mellitus and hyperlipidaemia were diagnosed in 48 (11.9%) and 84 (20.8%) individuals respectively. Positive Anti-tTGs were found in 14/403 (3.4%) and 13/403 (3.2%, 95% CI 1.5–4.9) had coeliac disease according to the modified Marsh classification; 8 had type I, 3 type II, 1 type IIIA and 1 type IIIB lesions.ConclusionAccording to our data, prevalence of CD in the subjects with NAFLD is higher than the rates reported in the general population. Therefore screening for CD in selected cases of NAFLD may be appropriate.     

Association of non-alcoholic fatty liver disease with microvascular complications of type 2 diabetes

IntroductionNon-alcoholic fatty liver disease (NAFLD) affects risks of type 2 diabetes (T2D), diabetes-related complications, and cardiovascular disease in a complex manner. This study is designed to clarify associations of sonographically-detected NAFLD and serum liver enzymes with diabetes-related microvascular complications.MethodsA matched case-contorl study was designed for 440 patients with T2D and at least one of the chronic diabetes-related microvascular complications and 495 age- and gender-matched control patients with T2D.ResultsConsidering pre-existing and newly developed chronic microvascular complications, diabetic peripheral neuropathy was found in 347 out of 935 (37.1%) study patients, diabetic retinopathy in 141/935 (15.1%), and diabetic nephropathy in 103/935 (11.0%). Diagnosis of diabetic retinopathy and diabetic nephropathy were inversely associated with the presence of NAFLD in the crude logistic regressions (OR [95% CI] = 0.18 [0.05–0.63], p value = 0.007; OR [95% CI] = 0.17 [0.04–0.59], p value = 0.011, respectively). The subgroup of NAFLD with elevated liver enzymes had lower odds of having diabetic peripheral neuropathy in the fully adjusted model (OR [95% CI] = 0.34 [0.12–0.98], p value = 0.048).ConclusionDiagnosis of NAFLD with or without elevated serum liver enzymes was inversely correlated with certain chronic diabetes microvascular complications. Possible explanations for this counter-intuitive and unexpected finding are discussed and center on reverse-causality, wherein sicker patients may develop beneficial compensatory physiological and behavioral adaptations. Diversity of studied patients, in particular with regards to the ethnic and racial differences among the Western and Asian populations may also partly account for contrasting findings of the relationship between NAFLD and microvascular complications of diabetes.     

Serum Ferritin level,microalbuminuria and non-alcoholic fatty liver disease in type 2 diabetic patients

BackgroundNon-alcoholic fatty liver disease (NAFLD) was considered one of the most common causes of chronic liver disease and is considered the hepatic manifestation of type 2 diabetes mellitus (T2DM). The factors that lead to marked fibrosis and liver cell injury in NAFLD are still remaining undiscovered.Patients and methodsThis study included (40) type 2 diabetic patients with NAFLD and (40) diabetic patients without NAFLD beside 15 healthy persons as a control group. All of them were subjected to full history taking, thorough clinical examination with especial stress on body weight (BW), height, body mass index (BMI), waist-hip ratio, blood pressure. Laboratory tests included serum total cholesterol (TC), triglycerides (TG), low density lipoprotein (LDL) and high-density lipoprotein (HDL), fasting blood glucose (FBG) and 2-h postprandial blood glucose (PBG), serum Ferritin and urine microalbuminuria (MAU).ResultsDuration of diabetes, BW, BMI and blood pressure were significantly higher in NAFLD group (P = 0.001). FBG, PBG, TC, TG, LDL, serum Ferritin and MAU were significantly increased in NAFLD group with significant difference between two studied groups as regard HDL. There was a highly significant correlation between serum Ferritin with BW, BMI, duration of diabetes, TC, TG, LDL and MAU. There was a significant correlation between serum Ferritin with age, waist hip ratio, duration of diabetes, SBP, FBG, PBG and HDL. There was a significant correlation between MAU and age, weight, BMI, waist hip ratio, duration of diabetes, DBP, FBG TC, TG, LDL and HDL.ConclusionNAFLD is a common liver disorder in diabetic patients. NAFLD is significantly associated with microalbuminuria and elevated serum Ferritin.     

非酒精性脂肪性肝病合并2型糖尿病患者血浆促甲状腺激素水平变化及其临床意义*

目的 研究非酒精性脂肪性肝病（NAFLD）合并2型糖尿病（T2DM）患者血清促甲状腺激素（TSH）水平的变化及其临床意义。方法 纳入NAFLD合并T2DM患者43例和T2DM患者40例,比较两组年龄、性别、身高、体质指数（BMI）、血压和血生化指标及血清糖化血红蛋白（HbAlc）、空腹胰岛素（FINS）、游离三碘甲状腺原氨酸（FT3）、游离甲状腺素（FT4）、促甲状腺激素（TSH）等指标的差异,采用Logistic回归分析影响NAFLD患者发生T2DM的独立危险因素。结果 NAFLD合并T2DM患者体质指数（BMI）为（28.4±3.8） kg/m²,显著大于T2DM患者的（23.8±3.1） kg/m²,P<0.05）; NAFLD合并T2DM患者血清ALT、AST、GGT、TG、HOMA-IR和TSH水平显著高于T2DM患者（P<0.05）;不同血清TSH的NAFLD患者血清TC、TG、LDL-C和FT3水平存在显著性差异（P<0.05）;经Logistic回归分析显示,BMI（RR=1.720,95%CI为1.154~3.015）、HOMA-IR（RR=2.632,95%CI为1.010~3.654）、血清TSH（RR=2.577,95%CI为1.214~3.689）和TG水平（RR=1.538,95%CI为1.240~2.658）是影响NAFLD患者发生T2DM的独立危险因素。结论 了解NAFLD患者发生T2DM的危险因素有助于早期预防和干预,检测血清TSH水平可能对筛查合并T2DM的NAFLD患者有一定的临床意义。     

2型糖尿病合并非酒精性脂肪肝动物模型的建立

目的用高脂饲料喂养2型糖尿病MKR鼠建立2型糖尿病并发非酒精性脂肪肝（NAFLD）动物模型。方法用高脂饲料诱发MKR鼠形成NAFLD模型,观察其肝脏形态、糖耐量、肝功能和血脂变化。结果高脂饲料诱发MKR鼠形成NAFLD模型肝细胞呈小泡性脂变,细胞内有大小不一的脂滴存在;糖耐量异常,异常程度高于MKR组。与C57野生组比较,MKR组小鼠肝质量、肝指数和血脂LDL-C升高差异无统计学意义（P〉0.05）,肝功能指标ALT、AST和血脂TG、TCHO、HDL-C升高差异有统计学意义（P〈0.05或0.01）;MKR高脂组小鼠肝质量、肝指数、肝功能指标（ALT、AST）和血脂（TCHO、HDL-C、LDL-C）进一步升高,高于MKR组（P〈0.05或0.01）,而TG下降,低于MKR组（P〈0.01）,高于C57野生组小鼠（P〈0.05）。结论高脂饲料喂养MKR鼠可以建立稳定的、与临床2型糖尿病并发NAFLD一致的动物模型。     

Histopathological differences utilizing the nonalcoholic fatty liver disease activity score criteria in diabetic (type 2 diabetes mellitus) and non-diabetic patients with nonalcoholic fatty liver disease

AIM: To study clinical and histopathological features of nonalcoholic fatty liver disease(NAFLD) in patients with and without type 2 diabetes mellitus(T2DM) using updated nonalcoholic steatohepatitis clinical research network(NASH-CRN) grading system.METHODS: We retrospectively analyzed data of 235 patients with biopsy proven NAFLD with and without T2 DM.This database was utilized in the previously published study comparing ethnicity outcomes in NAFLD by the same corresponding author.The pathology database from University of Chicago was utilized for enrolling consecutive patients who met the criteria for NAFLD and their detailed clinical and histopathology findings were obtained for comparison.The relevant clinical profile of patients was collected from the Electronic Medical Records around the time of liver biopsy and the histology was read by a single well-trained histopathologist.The updated criteria for type 2 diabetes have been utilized for analysis.Background data of patients with NASH and NAFLD has been included.The mean differences were compared using χ2 and t-test along with regression analysis to evaluate the predictors of NASH and advanced fibrosis.RESULTS: Patients with NAFLD and T2 DM were significantly older(49.9 vs 43.0,P 0.01),predominantly female(71.4 vs 56.3,P 0.02),had higher rate of metabolic syndrome(88.7 vs 36.4,P 0.01),had significantly higher aspartate transaminase(AST)/alanine transaminase(ALT) ratio(0.94 vs 0.78,P 0.01) and Fib-4 index(1.65 vs 1.06,P 0.01) as markers of NASH,showed higher mean NAFLD activity score(3.5 vs 3.0,P = 0.03) and higher mean fibrosis score(1.2 vs 0.52,P 0.01) compared to patients with NAFLD without T2 DM.Furthermore,advanced fibrosis(32.5 vs 12.0,P 0.01) and ballooning(27.3 vs 13.3,P 0.01) was significantly higher among patients with NAFLD and T2 DM compared to patients with NAFLD without T2 DM.On multivariate analysis,T2 DM was independently associated with NASH(OR = 3.27,95%CI: 1.43-7.50,P 0.01) and advanced fibrosis(OR = 3.45,95%CI: 1.53-7.77,P 0.01) in all patients with NAFLD.There was a higher rate of T2DM(38.1 vs 19.4,P 0.01) and cirrhosis(8.3 vs 0.0,P = 0.01) along with significantly higher mean Bilirubin(0.71 vs 0.56,P = 0.01) and AST(54.2 vs 38.3,P 0.01) and ALT(78.7 vs 57.0,P = 0.01) level among patients with NASH when compared to patients with steatosis alone.The mean platelet count(247 vs 283,P 0.01) and high-density lipoprotein cholesterol level(42.7 vs 48.1,P = 0.01) was lower among patients with NASH compared to patients with steatosis.CONCLUSION: Patients with NAFLD and T2 DM tend to have more advanced stages of NAFLD,particularly advanced fibrosis and higher rate of ballooning than patients with NAFLD without T2 DM.     

非酒精性脂肪性肝病分级分期管理研究进展

非酒精性脂肪性肝病（NAFLD）是代谢综合征在肝脏的病理学表现。由于饮食结构的改变,NAFLD发病率呈现上升趋势,且NAFLD与肝病进展、糖尿病和心血管疾病死亡密切相关。因此,寻求NAFLD患者综合管理方法迫在眉睫。本文综述了NAFLD分级、分期、治疗和随访评估的研究进展,以期指导临床诊断、治疗和管理。     

非酒精性脂肪性肝病合并2型糖尿病患者血清铁蛋白变化及其临床意义

目的 探讨非酒精性脂肪性肝病(NAFLD)合并2型糖尿病(T2DM)患者血清铁蛋白(SF)的变化及其临床意义.方法 本文纳入633例NAFLD合并T2DM、163例T2DM和163例NAFLD患者,检测血清SF和其他血清指标,应用二分类Logistic多元回归分析.结果 NAFLD合并T2DM患者血清SF水平为(293...     

达格列净联合利拉鲁肽治疗非酒精性脂肪性肝病合并2型糖尿病患者短期疗效研究

目的 探讨应用达格列净联合利拉鲁肽治疗非酒精性脂肪性肝病(NAFLD)合并2型糖尿病(T2MD)患者的短期疗效。方法 2017年9月～2020年10月我院收治的60例NAFLD合并T2MD患者,采用随机数字表法将其分为观察组30例和对照组,均常规接受生活方式干预和二甲双胍口服控制血糖,在此基础上给予对照组利拉鲁肽治疗,观察组在对照组治疗的基础上给予达格列净口服,两组均持续治疗观察3个月。常规检测空腹血糖(FPG)、餐后2 h血糖(2h PG)、糖化血红蛋白(HbA1c)及甘油三酯(TG)、总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)和高密度脂蛋白胆固醇(HDL-C)水平;使用自动免疫分析仪检测空腹胰岛素(Fins)和餐后2 h胰岛素(2hIns)水平,计算胰岛素抵抗指数(HOMA-IR);使用Fibrotouch检测肝脏脂肪受控衰减参数(CAP)。结果 在治疗3个月末,观察FPG、2hPG和HbA1水平分别为(5.8±0.7)mmol/L、(6.9±0.8)mmol/L和(6.3±0.9)%,显著低于对照组【分别为(6.6±0.6)mmol/L、(7.7±0.7)mmol/L和(...     

2型糖尿病合并非酒精性脂肪性肝病的研究进展

非酒精性脂肪性肝病(NAFLD)是以肝细胞脂肪变性和脂肪蓄积为病理特征,但无过量饮酒史的临床综合征,它是代谢综合征在肝脏的表现.胰岛素抵抗是NAFLD与2型糖尿病的共同发病基础.NAFLD是转氨酶慢性升高的常见原因之一.转氨酶升高在2型糖尿病患者中的发生率明显高于普通人群,并与心血管危险因素的聚集有关.运动和节制饮食可控制体重、改善胰岛素抵抗、纠正血脂紊乱和减轻脂肪肝.二甲双胍和格列酮类可降低血转氨酶水平和部分逆转脂肪肝组织学变化.     

非酒精性脂肪性肝病合并2型糖尿病患者血清抵抗素和黄醇结合蛋白4水平及其临床意义探讨

目的 探讨非酒精性脂肪性肝病(NAFLD)合并2型糖尿病(T2DM)血清抵抗素和黄醇结合蛋白4(RBP4)水平变化及其临床意义。方法 2017年10月～2021年1月我院诊治的NAFLD合并T2DM患者106例和NAFLD患者106例,检测空腹血糖(FBG),采用化学发光法检测空腹胰岛素(FINS)水平,计算HOMA-β指数和胰岛素抵抗指数(HOMA-IR),采用ELISA法检测血清抵抗素、RBP4、肿瘤坏死因子(TNF-α)和白介素(IL-6)水平。结果 合并T2DM患者血清TC和HDL-C水平分别为(4.7±0.5)mmol/L和(1.1±0.2)mmol/L,显著低于NAFLD患者【分别为(5.6±0.6)mmol/L和(1.4±0.3)mmol/L,P<0.05】;合并T2DM患者血清GGT水平(102.3±15.5)U/L,显著高于NAFLD患者【(71.6±4.6),P<0.05】,而两组血清ALT、AST和ALP水平无显著性差异(P>0.05);合并T2DM患者血清FBG、FINS和HOMA-IR水平分别为(7.7±0.8)mmol/L、(6.7±1.2...     

Sarcopenia is associated with non-alcoholic fatty liver disease in men with type 2 diabetes

AimsRecent epidemiological studies have suggested an association between sarcopenia and non-alcoholic fatty liver disease (NAFLD) in the general population, prompting our investigation into the gender-specific association between sarcopenia and NAFLD in patients with type 2 diabetes mellitus (T2DM).MethodsIn this cross-sectional study, 4210 patients with T2DM were recruited from the Seoul Metabolic Syndrome Cohort. Appendicular skeletal muscle mass (ASM) was estimated from bioimpedance analysis measurements, and the skeletal muscle mass index (SMI) was calculated by dividing the sum of ASM by body weight. Sarcopenia was defined as a gender-specific SMI value > 2 standard deviations (SDs) below the mean for healthy young adults. NAFLD was defined as the presence of hepatic steatosis on ultrasonography with no other causes of chronic liver disease.ResultsAmong the entire study population (mean age: 57.4 ± 10.8 years), 1278 (30.4%) had NAFLD and 1240 (29.5%) had sarcopenia, and the prevalence of NAFLD was significantly higher in those with sarcopenia: 46.2% vs 25.1% (P < 0.001) in men; 38.3% vs 25.4% (P < 0.001) in women. Sarcopenia was significantly associated with higher risk of NAFLD in men (adjusted odds ratio [OR]: 1.58, 95% confidence interval [CI]: 1.15–2.17), whereas the association was attenuated in women after adjusting for clinical risk factors.ConclusionSarcopenia is independently associated with NAFLD in men with T2DM, which suggests that sarcopenia may be a risk factor for NAFLD in men with T2DM.     

非酒精性脂肪性肝病患者血清脂联素和瘦素水平变化

目的研究血清脂联素和瘦素水平与非酒精性脂肪性肝病(NAFLD)的关系。方法应用放射免疫分析法检测56例NAFLD患者和42例健康人血清脂联素、瘦素、总胆固醇、甘油三酯、高密度脂蛋白胆固醇、低密度脂蛋白胆固醇、载脂蛋白ApoA、ApoB、胰岛素、胰岛素抵抗指数、体质量指数。结果对照组和NAFLD患者血清脂联素分别为12.4±3.2mg/L和6.1±1.9mg/L(P<0.01),高密度脂蛋白胆固醇为1.2±0.3mmol/L和1.0±0.3mmol/L(P<0.05),瘦素为5.3±1.4μg/L和9.2±2.1μg/L(P<0.01),胰岛素为9.4±4.2IU/L和18.5±7.8IU/L(P<0.01),甘油三酯为1.0±0.5mmol/L和2.4±1.2mmol/L(P<0.01),低密度脂蛋白胆固醇为2.2±0.6mmol/L和2.8±0.7mmol/L(P<0.05),体质量指数为21.5±2.1kg/m2和28.3±3.2kg/m(2P<0.01),胰岛素抵抗为1.1±0.4IU/mmol和3.8±2.21u/mmo(lP<0.01);脂联素水平与瘦素、体质量指数和胰岛素抵抗呈负相关(r=-0.552,-0.497,-0.513,P均<0.01)。结论 NAFLD患者血清脂联素水平下降,瘦素水平升高,且与胰岛素抵抗相关。